JP2017538439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538439A5 JP2017538439A5 JP2017538915A JP2017538915A JP2017538439A5 JP 2017538439 A5 JP2017538439 A5 JP 2017538439A5 JP 2017538915 A JP2017538915 A JP 2017538915A JP 2017538915 A JP2017538915 A JP 2017538915A JP 2017538439 A5 JP2017538439 A5 JP 2017538439A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- item
- seq
- nodal
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 49
- 230000000694 effects Effects 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- 210000000416 exudates and transudate Anatomy 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- -1 serum Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 239000003814 drug Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 101150101604 ACVR1B gene Proteins 0.000 description 1
- 102000002092 Left-Right Determination Factor Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 101000967919 Mus musculus Left-right determination factor 1 Proteins 0.000 description 1
- 102000044547 Nodal Human genes 0.000 description 1
- 108700024442 Nodal Proteins 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- 102000057208 Smad2 Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060974P | 2014-10-07 | 2014-10-07 | |
| US62/060,974 | 2014-10-07 | ||
| PCT/US2015/054515 WO2016057683A2 (en) | 2014-10-07 | 2015-10-07 | Novel anti-nodal antibodies and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538439A JP2017538439A (ja) | 2017-12-28 |
| JP2017538439A5 true JP2017538439A5 (cg-RX-API-DMAC7.html) | 2018-11-08 |
| JP6574257B2 JP6574257B2 (ja) | 2019-09-11 |
Family
ID=55653941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538915A Active JP6574257B2 (ja) | 2014-10-07 | 2015-10-07 | 新規の抗Ｎｏｄａｌ抗体及びその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US9688750B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3204414B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6574257B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016057683A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2907521C (en) | 2013-03-21 | 2021-04-13 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| EP2976331B1 (en) | 2013-03-21 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Synthesis of hydantoin containing peptide products |
| WO2016057683A2 (en) | 2014-10-07 | 2016-04-14 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Novel anti-nodal antibodies and methods of using same |
| WO2018127494A1 (en) * | 2017-01-03 | 2018-07-12 | Deinobiotics | Methods of producing lipolanthipeptides |
| US11331019B2 (en) | 2017-08-07 | 2022-05-17 | The Research Foundation For The State University Of New York | Nanoparticle sensor having a nanofibrous membrane scaffold |
| EP4574176A3 (en) * | 2018-06-05 | 2025-09-17 | University of Mississippi Medical Center | Production of sized macro- and micro- elp particles for drug delivery |
| SG11202100721SA (en) | 2018-07-23 | 2021-02-25 | Univ Alberta | Genetically-encoded bicyclic peptide libraries |
| WO2020154215A1 (en) * | 2019-01-26 | 2020-07-30 | Chien, Du-Shieng | Nodal regulation of cancer drug resistance gene |
| WO2022051495A1 (en) * | 2020-09-02 | 2022-03-10 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
| KR102763290B1 (ko) * | 2021-09-16 | 2025-02-05 | 동아대학교 산학협력단 | 신규한 샤르코-마리-투스병 제1a형 진단 또는 예후 예측용 바이오마커 및 이의 용도 |
| CN119592689A (zh) * | 2024-11-19 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | SMAD2、p38 MAPK作为评估免疫治疗黏膜黑色素瘤效果的标志物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| DE69228247T2 (de) | 1991-08-10 | 1999-07-08 | Medical Research Council, London | Behandlung von Zellpopulationen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US20020086351A1 (en) * | 1998-08-20 | 2002-07-04 | Reinhard Ebner | Human nodal and lefty homologues |
| EP2412383A1 (en) * | 2006-07-28 | 2012-02-01 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| JPWO2009051220A1 (ja) * | 2007-10-19 | 2011-03-03 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| WO2009080773A1 (en) * | 2007-12-24 | 2009-07-02 | Dsm Ip Assets B.V. | Convergent synthesis of renin inhibitors and intermediates useful therein |
| EP4083072A1 (en) | 2008-10-06 | 2022-11-02 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| EP2488867B1 (en) * | 2009-10-14 | 2020-09-30 | Janssen Biotech, Inc. | Methods of affinity maturing antibodies |
| SG10201801444WA (en) * | 2012-02-24 | 2018-04-27 | Abbvie Stemcentrx Llc | Anti sez6 antibodies and methods of use |
| WO2016057683A2 (en) | 2014-10-07 | 2016-04-14 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Novel anti-nodal antibodies and methods of using same |
-
2015
- 2015-10-07 WO PCT/US2015/054515 patent/WO2016057683A2/en not_active Ceased
- 2015-10-07 US US14/877,617 patent/US9688750B2/en active Active
- 2015-10-07 EP EP15849199.3A patent/EP3204414B1/en active Active
- 2015-10-07 JP JP2017538915A patent/JP6574257B2/ja active Active
-
2017
- 2017-06-27 US US15/634,355 patent/US10508147B2/en active Active
-
2018
- 2018-02-13 US US15/895,771 patent/US10494428B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538439A5 (cg-RX-API-DMAC7.html) | ||
| CN103562403B (zh) | 一个识别肿瘤起始细胞的抗体和抗原及其应用 | |
| JP2020500003A5 (cg-RX-API-DMAC7.html) | ||
| US20200157218A1 (en) | Bispecific antibodies to ror1 and cd3 | |
| JP2010523096A5 (cg-RX-API-DMAC7.html) | ||
| US9683032B2 (en) | Anti-S100A4 antibody molecules and their uses | |
| AU2020293160B2 (en) | Anti-CD25 antibody and application thereof | |
| US20220119546A1 (en) | Plectin-1 binding antibodies and uses thereof | |
| KR20170039074A (ko) | Tmcc3의 억제에 의한 암 저해 방법 | |
| CN112243443A (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
| JP6977105B2 (ja) | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 | |
| WO2012063839A1 (ja) | 抗１本鎖ｉｖ型コラーゲンポリペプチド抗体、並びに該抗体を含む医薬、及び腫瘍の診断薬、予防薬、又は治療薬 | |
| JP7086607B2 (ja) | Ｉｇｆ－１ｒ抗体および癌の診断のためのその使用 | |
| US20210253691A1 (en) | Methods for improving response to anti-lif antibody treatment in individuals with cancer | |
| CN121008043A (zh) | Axl-gas6复合物的检测方法及在心肌梗死患者中的应用 | |
| CN120058950A (zh) | 抗adam9的抗体及其用途 | |
| CN118994393A (zh) | 一种抗fgfr2抗体及其应用 | |
| CN121108358A (zh) | 一种抗gpc3×cd3双特异性抗体及其制备方法和用途 | |
| CN121108357A (zh) | 抗amhr2×cd3双特异性抗体及其制备和用途 | |
| CN118591554A (zh) | 抗人cxcl1抗体 | |
| HK40036076B (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| HK40036076A (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| HK1248730B (zh) | Igf-1r抗体及其用於癌症诊断的用途 | |
| HK1243434B (zh) | Igf-1r抗体及其诊断癌症的用途 | |
| BR112017022635B1 (pt) | Anticorpo anti-igf-1r, kits, e métodos para a detecção in vitro ou ex vivo da presença e/ou localização de células tumorais expressando igf-1r em um indivíduo, para a detecção in vitro ou ex vivo da percentagem de células tumorais que expressam igf-1r em um indivíduo, para a determinação in vitro ou ex vivo do nível de expressão de igf-1r em células tumorais em um indivíduo, para a determinação in vitro ou ex vivo da pontuação de igf-1r de células tumorais ou de um tumor em um indivíduo, para determinar se um transtorno oncogênico é suscetível ao tratamento com uma droga de anticorpo tendo como alvo a via de igf-1r, para a determinação in vitro ou ex vivo da eficácia de um regime terapêutico conce(...) |